Paxil Maker Publishes Study on Children and Antidepressants

NPR | By Joanne Silberner

Published June 15, 2004 at 12:00 AM EDT

GlaxoSmithKlein, the manufacturer of the antidepressant Paxil, has released on its company Web site reports of unpublished clinical tests of that drug in children and adolescents suffering from depression. Paxil is not approved for use in children but some doctors have prescribed it off label. SmithKline officials have denied that they selectively disclosed clinical trial findings. This is the first time that this data on Paxil have been made public and NPR's Joanne Silberner looks at whether it will give a different picture of the safety and efficacy of the drug.

Joanne Silberner

Joanne Silberner is a health policy correspondent for National Public Radio. She covers medicine, health reform, and changes in the health care marketplace.

See stories by Joanne Silberner

Federal funding is gone.

Congress has eliminated all funding for public media.

That means $2.1 million per year that Connecticut Public relied on to deliver you news, information, and entertainment programs you enjoyed is gone.

The future of public media is in your hands.

All donations are appreciated, but we ask in this moment you consider starting a monthly gift as a Sustainer to help replace what’s been lost.

Donate

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

Federal funding is gone.

Donate